...Senátorka MUDr. Alena Dernerová píše pro měsíčník Občan v síti analýzu kontrolní činnosti při čerpání evropských peněz na nákup zdravotnických přístrojů. V článku najdete zajímavou tabulku porovnání běžných cen přístrojů s cenami, které "vysoutěžily" kompletátorské firmy nejen v Krajské zdravotní, ale i ve státem řízených nemocnicích...
26.02.11
Ceník přístrojů od kompletátorů - porovnejte
MEDICAL TRIBUNE CZ > Ceník přístrojů od kompletátorů - porovnejte
Prostate Cancer Survival Unhurt by Intermittent Androgen Suppression - OncologySTAT
Prostate Cancer Survival Unhurt by Intermittent Androgen Suppression - OncologySTAT
...Continuous, lifelong androgen deprivation using an LHRH analogue has been the standard of care for men with PSA failure after radical prostate radiotherapy for the past 20 years. PR7 is a large, well-conducted phase III trial that compares this approach with intermittent therapy, using the LHRH analogue for 8 months at a time and then withholding further therapy until the PSA rises above 10 ng/mL. The trial provides good quality evidence that intermittent therapy is as effective as continuous treatment, and that in using the intermittent approach, patients will spend the majority of time off treatment. Given that intermittent therapy will be considerably cheaper than continuous treatment, and less morbid, it should be regarded as the new standard of care for men with PSA failure after radiotherapy......
16.02.11
14.02.11
11.02.11
TNM klasifikace 7.vydání
tnm_7th_edition_summary_
Klasifkace vešla v platnost 1. ledna 2011 sdělením ČSÚ č. 324 ze dne 19. listopadu 2010.
Klasifikaci je možno zakoupit v nakladatelství BOMTON agency, s.r.o., Václavské náměstí 819/43, 110 00 Praha 1 a dále v elektronickém obchodě na adrese http://mkn-10.inshop.cz/. (zdroj UZIS)
06.02.11
Dexpanthenol
Dutina ústní
Rp.
Dexpanthenoli 5,0
Natrii benzoatis 0,15
Acidi citrici monohydr. 0,11
Aquae purificatae ad 100,0
M. f. sol.
užití
Rp.
Dexpanthenoli 5,0
Natrii benzoatis 0,15
Acidi citrici monohydr. 0,11
Aquae purificatae ad 100,0
M. f. sol.
užití
- 1–3× denně nanášet na postižená místa
- Výplachy úst a vlhké krytí: roztok se před použitím naředí stejným dílem čerstvě převařené vody
- Výplachy úst: 3–4× denně asi 5–10 ml takto naředěného roztoku se 3 minuty ponechá v ústech
Popáleniny , radiační dermatitis
Rp.
Dexpanthenoli 5,0
Glyceroli 85% 10,0
Alcoholis cetylstearylici 6,0
Glyceroli monostearatis 45–55 5,5
Polysorbati 80 2,0
Dimeticoni 2,0
Paraffini perliquidi 20,0
Aquae purificatae ad 100,0
M. f. crm
D. S. 1–3× denně nanášet na postižená místa.
Oleokrém
Rp.
Dexpanthenoli 5,0
Amygdalae olei raffin. 7,0
Aquae purificatae 30,0
Lanae alcohol. ung. 58,0
M. f. ung
D. S. Nanášet 1–3x denně
Suchá kůže
Rp.
Dexpanthenoli
Ureae aa 5,0
Acidi lactici 1,0
Natrii lactatis sol. 50% 4,0
Glyceroli 85% 2,0
Dimeticoni 6,0
Aquae purificatae 14,0
Cutilan ad 100,0
M. f. crm
D. S. Potírat několikrát denně.
zdroj
Fytoterapie
Aloe vera
Čubet benedykt Cnicus benedictus L.
Kostival lékařský Symphytum officinale L
Kurkuma
Meduňka lékařská Melissa officinalis L
Pohanka obecná Fagopyrum esculentum
Rakytník řešetlákový Hippophae rhamnoides
Třapatka nachová Echinacea purpurea
Šalvěj lékařská Salvia officinalis L.
Čubet benedykt Cnicus benedictus L.
Kostival lékařský Symphytum officinale L
Kurkuma
Meduňka lékařská Melissa officinalis L
Pohanka obecná Fagopyrum esculentum
Rakytník řešetlákový Hippophae rhamnoides
Třapatka nachová Echinacea purpurea
Šalvěj lékařská Salvia officinalis L.
Adultní tumor z buněk granulozy
Ve zkratce
- nonepieteliální
- hormonální sekrece - nejčastěji estrogeny, vzácněji androgeny
- max.výskyt kolem 60-ti let, jednostranně
- u 1/4 pacientek hyperplazie endometria až adenoca (sekrece estrogenů)
- klinika - UZ cystické pánevní rezistence v peri a postmenopauzálním věku
- 50% produkce protein S100-B
- nádory do 5 cm stadia IA lze při příznivých histopatologických kriteriích ponechat pouze na dispenzarizaci - dispenzarizace doživotní - možnost recidivy v dlouholetém odstupu
- prognostické faktory - kompletní operační výkon,nepřítomnost ruptury, velikost nádoru, jaderné atypie
- jinak chemoth - DDP, ADB , nebo BEP
- prognóza příznivá
Články
- Nonepiteliální ZN ovarií – úskalí diagnostiky a managementu Číslo abstraktu: 024 Autoři: Kačírek J., Rob L., Robová H., Pluta M.
- Prognostic factors in ovarian adult granulosa cell tumour J klin Pathol2008, 61
Odkazy
Roche appeals FDA decision on Avastin - Cancer Network
Roche appeals FDA decision on Avastin - Cancer Network
...European Medicines Agency has already confirmed that the benefits of Avastin in combination with paclitaxel outweigh the risks and considers this a viable treatment option in women with metastatic breast cancer.,,,
New Target, Drug Potential Found for Colon Cancer
New Target, Drug Potential Found for Colon Cancer
In a study published online January 31st in the Journal of the National Cancer Institute, researchers from the Institute of Cancer Research (ICR) found that Sprycel, known generically as dasatinib and already used in other cancers, reduced bowel cancer cell growth in the lab by blocking the effects of an enzyme called lysyl oxidase, or LOX.
Calcium-Magnesium Combo Eases Oxaliplatin Sensory Effects
Calcium-Magnesium Combo Eases Oxaliplatin Sensory Effects
...The original plan had been to enroll 300 patients. But when only a third of that number had been randomized, unsubstantiated data from a separate trial testing FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for colon cancer suggested that giving magnesium and calcium reduced the effectiveness of the treatment. Later, an independent review of that other trial eventually showed that in fact the magnesium/calcium group had a higher tumor response rate, but by then the current study had been closed.
The report by Dr. Loprinzi and colleagues includes data on 102 colon cancer patients on FOLFOX who received 1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin, or placebo. Data cutoff was done after four months and one week....
Analysis: New Mammography Guidelines Will Cost Lives - OncologySTAT
Analysis: New Mammography Guidelines Will Cost Lives - OncologySTAT
...Prior to that time, the USPSTF - and other organizations - recommended screening mammography every 1-2 years for women beginning at age 40. The ACS recommends annual screening mammography starting at age 40....
Molecular Markers May Improve Selection of Patients With Pancreatic Cancer for Surgery - OncologySTAT
Molecular Markers May Improve Selection of Patients With Pancreatic Cancer for Surgery - OncologySTAT
...in the cohort of 372 patients who underwent surgical resection for pancreatic cancer, the markers S100A2 and S100A4, which are associated with more aggressive tumor behavior, predicted worse survival after surgery.
Median survival was almost three times longer when a tumor was immunohistochemically negative for both markers, compared with positive for S100A2 (34.3 vs. 11.9 months). A third group of patients having tumors positive only for S100A4 had intermediate survival (15.6 months)....
ERCC1 Expression Predicts Treatment Outcome in Esophageal Adenocarcinoma - OncologySTAT
ERCC1 Expression Predicts Treatment Outcome in Esophageal Adenocarcinoma - OncologySTAT
...Pretreatment expression of ERCC1 in localized esophageal and gastroesophageal adenocarcinomas is a marker for outcomes among patients given trimodality therapy that includes oxaliplatin-based chemoradiation, investigators reported from a prospective study.
Fully 58% of the 55 patients studied from the Southwest Oncology Group (SWOG) S0356 trial had tumors expressing a high level of mRNA for ERCC1, a key gene in the repair of platinum- and radiation-induced DNA damage.
Adding Bevacizumab to Chemo Raises Treatment-Related Mortality - OncologySTAT
Adding Bevacizumab to Chemo Raises Treatment-Related Mortality - OncologySTAT
...Treatment with taxanes and platinum agents appeared to raise the risk of fatal events associated with bevacizumab. This may reflect an interaction between these classes of drugs and bevacizumab...
FDA Warns of Possible Link Between Breast Implants and Rare Cancer - OncologySTAT
FDA Warns of Possible Link Between Breast Implants and Rare Cancer - OncologySTAT
The Food and Drug Administration is asking health care professionals to report any confirmed cases of anaplastic large cell lymphoma (ALCL) in women with silicone gel- or saline-filled breast implants, citing concerns about a possible association.
The Food and Drug Administration is asking health care professionals to report any confirmed cases of anaplastic large cell lymphoma (ALCL) in women with silicone gel- or saline-filled breast implants, citing concerns about a possible association.
Přihlásit se k odběru:
Příspěvky (Atom)